Fusion Still Holds Strong in Spine Surgery

The dominant area of technologies and products for the management of spine disorders (despite a myriad of new technology alternatives) remains, and will remain, the use of posterior pedicle screw fusion systems. This well established approach accounts for over over 20% of the total global sales of spine surgery products and will continue to grow (despite even more dramatic growth of other spine technologies) to nearly a quarter of all sales during the next ten years. Other areas of product and market development are growing at rates as high as 33% annually and as low as 4% annually. Despite pressures from cost containment in healthcare that are squeezing prices on spine surgery products and challenging growth in procedure volume rates, the field of spine surgery remains one of the strongest medtech markets, according to a new report from MedMarket Diligence, LLC.

“Worldwide Spine Surgery 2011: Products, Technologies, Markets & Opportunities, 2010-2020”, Report #M520, details the global market for spine surgery technologies including Posterior Pedical Screw Fusion Systems, ACP Systems, ALIF, TLIF, PLIF, AxiaLIF, ISP Systems, Cervical Artificial Discs, Lumbar Artificial Discs, Vertebroplasty, Balloon Kyphoplasty, Allografts, Demineralized Bone Matrix, and Bone Morphogenetic Proteins. The report provides a global analysis of the current and forecast market, with market shares, for these products. Individual countries and regional markets detailed include Americas (USA, Canada, Mexico, Brazil), European Union (United Kingdom, Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (Japan, China, India, Australia/New Zealand) and Rest of World.

For more information, contact MedMarket Diligence, LLC. Report #M520.

Author

PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

View all posts by PatrickDriscoll